Collegium Pharmaceutical stock edges lower as analysts keep Moderate Buy stance

Collegium Pharmaceutical stock (ISIN US19459E1029) closed at USD 22.31 on Nasdaq on September 18, 2026, down 0.3% for the day and trading close to its 12-month low of USD 21.65 per share. According to MarketBeat on September 18, 2026, the stock still carries a consensus Moderate Buy rating, with an average 12-month price target of USD 48.50, more than double the latest closing price.

Analysts reiterate Moderate Buy with mixed target changes

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is currently covered by eight research firms that collectively assign a consensus recommendation of Moderate Buy, reflecting five buy ratings, two holds and one sell rating. According to MarketBeat on September 18, 2026, the average one-year price target across these brokerages stands at USD 48.50, implying upside of around 117% from the latest close of USD 22.31 if the consensus were reached.

Recent analyst actions on Collegium have been mixed, with some houses trimming targets while maintaining positive recommendations and others initiating coverage at optimistic levels. As reported by MarketBeat on September 18, 2026, Needham recently cut its price target to USD 46 but kept a buy rating, while Truist Financial initiated coverage with a buy rating and a USD 49 target, and Leerink Partners started coverage with an outperform rating and a USD 45 target. These individual targets cluster around the consensus figure and highlight that, despite short-term price weakness, many analysts continue to see value in the shares over the coming year.

Earnings beat and revenue growth underpin the investment case

The latest reported quarterly figures from Collegium provide context for the supportive analyst stance. In its most recent quarter, the company delivered earnings per share (EPS) of USD 1.92, which, according to MarketBeat on September 18, 2026, came in ahead of analyst estimates for the period. The same overview notes that revenue in this latest quarter reached USD 199.88 million, representing growth of 6.3% year over year and signaling that the company is still expanding its top line despite a challenging environment for specialty pharmaceutical names.

The combination of a revenue increase of 6.3% to USD 199.88 million in the latest reported quarter, compared with the prior-year period, and EPS of USD 1.92 that beat consensus forecasts, gives Collegium a fundamentally stronger profile than the depressed share price might suggest. According to the figures cited by MarketBeat, the EPS result outperformed expectations while the mid-single-digit revenue growth underscores a steady underlying demand for the company’s pain-management portfolio.

From an investor perspective, the quantified comparison between fundamentals and the share price is striking: EPS of USD 1.92 in the latest quarter, if annualized without adjustment, would imply a low single-digit price-earnings multiple at the current share price near USD 22, while the Moderate Buy consensus and the average target of USD 48.50 suggest that the market may be heavily discounting execution risk, regulatory uncertainty or competition in Collegium’s core segments rather than a deterioration in the reported numbers themselves. That discount is evident when comparing the present price near the 12-month low with the cluster of analyst targets in the mid-40s USD range.

Risks, valuation gap and next checkpoints for COLL stock

Despite the supportive earnings trajectory and analyst recommendations, Collegium Pharmaceutical stock has recently traded weakly, with the latest close of USD 22.31 only modestly above the 12-month low of USD 21.65 mentioned by MarketBeat. That proximity to the low end of the 12-month range illustrates a clear gap between market pricing and the fundamental picture that analysts outline. For holders of the stock, the key question is whether upcoming catalysts, such as further quarterly results or potential pipeline updates, can close some of that gap by reinforcing confidence in sustainable earnings and cash-flow generation.

Risks to the Collegium story include the broader scrutiny of opioid and pain-management therapies, competition from generics or alternative treatments and potential reimbursement pressure from payers. While the latest quarter’s numbers show revenue growth of 6.3% and an EPS beat, these outcomes remain subject to future changes in the regulatory and competitive landscape. The Moderate Buy consensus itself reflects this balance of opportunity and risk, with one sell rating and two hold ratings among the eight research firms tracked by MarketBeat, signaling that not all analysts view the stock as unequivocally attractive at current levels.

Collegium stock trades near 12-month low on Nasdaq

At the close of trading on Nasdaq on September 18, 2026, Collegium Pharmaceutical stock changed hands at USD 22.31, down USD 0.07 or 0.3% compared with the prior session, with 100,653 shares traded versus an average volume of 547,496 shares as reported by MarketBeat. With the shares trading close to their 12-month low of USD 21.65 and well below the average analyst target of USD 48.50, the current price level highlights both the market’s caution and the potential valuation gap that analysts see based on recent earnings performance and revenue growth.

More news and analyses on Collegium Pharmaceutical stock